Purpose: Increased numbers of patients with both lung cancer and atherosclerotic vascular disease (AVD) may be expected in the future. The aim of this study was to report the incidence of lung cancer in patients with AVD and to discuss patient characteristics and management. Method: A total of 638 patients who underwent AVD treatment were investigated. Results: Lung cancer was observed in 17 (2.7%) of 638 patients studied. The proportion of smoking history was significantly higher in patients with lung cancer (p = 0.0091).
Introduction
Lung cancer is the leading cause of cancer death both in Japan and worldwide, and the incidence of lung cancer increases with age. 1 Smoking is the predominant risk factor for the development of lung cancer. 2 Moreover, smoking status has been consistently reported to be a statistically significant prognostic factor in patients with lung cancer. 3 In addition, smoking and advanced age are conventional risk factors for vascular disease. 4 A recent systematic review of large studies of smoking-related outcomes demonstrated an association between smoking and aortic aneurysm. 5 Therefore, increased numbers of patients with both lung cancer and atherosclerotic vascular disease (AVD), including thoracic aortic aneurysm (TAA) or abdominal aortic aneurysm (AAA), aneurysm of extremity arteries, and arteriosclerotic obstructive disease (ASO), may be expected in the future. Several studies on patients with concomitant lung cancer and AAA have recently been reported. 6 7 Moreover, incidental findings of lung cancer in patients who underwent computed tomography
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Introduction
Lung cancer is the leading cause of cancer death both in Japan and worldwide, and the incidence of lung cancer increases with age. 1 Smoking is the predominant risk factor for the development of lung cancer. 2 Moreover, smoking status has been consistently reported to be a statistically significant prognostic factor in patients with lung cancer. 3 In addition, smoking and advanced age are conventional risk factors for vascular disease. 4 A recent systematic review of large studies of smoking-related outcomes demonstrated an association between smoking and aortic aneurysm. 5 Therefore, increased numbers of patients with both lung cancer and atherosclerotic vascular disease (AVD), including thoracic aortic aneurysm (TAA) or abdominal aortic aneurysm (AAA), aneurysm of extremity arteries, and arteriosclerotic obstructive disease (ASO), may be expected in the future. Several studies on patients with concomitant lung cancer and AAA have recently been reported. 6 7 Moreover, incidental findings of lung cancer in patients who underwent computed tomography The clinical staging examination for lung cancer consisted of a combination of dynamic computed tomography (CT) scans, magnetic resonance imaging, bone scintigraphy, or positron emission tomography. The follow-up after treatment of lung cancer consisted of chest X-ray, chest CT, abdominal CT, and bone scans; tumor markers were also checked.
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Statistical analysis
The � 2 test and Fisher's exact test were used for comparisons of the 2 periods. All results were considered to be significant at p values of <0.05. All statistical analyses were performed using the StatView software program, version 5.0.
Results
Frequency of lung cancer in patients with AVD
Lung cancer with AVD was observed in 17 (2.7%) of 638 patients studied ( Table 1 ). The characteristics of these 17 patients are shown in Table 2 . These patients ranged from 62 to 86 years of age (mean, 74 years) and included 15 men and 2 women. In terms of AVD 
Correlation between incidence of lung cancer and clinical factors in patients with AVD
The association between incidence of lung cancer and clinical features was examined ( Table 3 ). The incidence of lung cancer in patients with AVD was found to be significantly associated with smoking status (p = 0�0091). Moreover, patients with lung cancer smoked significantly more heavily than did those without lung cancer (p = 0�0073). No other factors (gender, age, or type of AVD) were found to be correlated with the incidence of lung cancer.
Distribution of patients according to the detected period of lung cancer and AVD
The distribution of patients according to the detected period of lung cancer and AVD is shown in Fig. 1 . Six and after AVD in 7. During the follow-up, lung cancer was detected prior to AVD in 3 of 4 (75%) patients, after AVD in 2 of 7 (28.6%) patients, and synchronously with AVD in 3 of 6 (50%) patients; all are still alive.
Characteristics and treatment of patients with lung cancer detected before detection of AVD All 4 patients were men and had stage IA lung cancer. Two patients had adenocarcinomas, 1 had squamous cell carcinoma, and 1 had small cell carcinoma. Three of 4 (75%) patients underwent surgical resections, and the remaining patient underwent chemoradiotherapy. During the follow-up period, 3 patients had AAA and the other had ASO, and 3 of 4 (75%) patients are living.
Characteristics and treatment of patients with lung cancer detected after AVD treatment
The profiles of 7 patients in whom AVD was metachronously detected prior to lung cancer are summarized in Table 4 . Lung cancer was found in all patients after AVD treatment. The time from AVD treatment to the diagnosis of lung cancer ranged from 12 to 198 months, with a mean of 62.5 months. Of the 7 patients, 5 (patients 1, 2, 4, 5, and 7) had advanced lung cancer (stage III or IV). As a result, only 2 patients (patients 3 and 6) with stage IA lung cancer who received radiotherapy or surgery are still alive.
Details of patients with concomitant AVD and lung cancer Table 5 shows the characteristics and treatments of 6 patients with concomitant AVD and lung cancer. 
Discussion
Several recent studies reported that the incidence of lung cancer in patients with AAA or ASO was 2.7% to 19.2%. 5 8 9 Catalano et al. performed a study in which lung cancer was found in 18 (2.3%) of 771 patients with atherosclerotic disease including TAA, AAA, and aneurysm of lower extremity arteries. 7 Thus, the frequency (2.7%) of lung cancer in patients with AVD was consistent, although the present study included ASO in addition to the aforementioned atherosclerotic diseases.
Moreover, the present study demonstrated 3 prominent facts. First, both smoking history and the packyear index were also risk factors of lung cancer in patients with AVD. Smoking is the major risk factor for lung cancer; it is also one of the main risk factors for peripheral arterial disease. Smoking is associated with a 4-fold increased risk for peripheral vascular disease, and the number of pack-years is associated with global atherosclerotic disease severity. 4 In addition, Thorgeirsson et al. recently indentified a variant in the nicotinic acetylcholine receptor gene cluster on chromosome 15q24, which conferred a risk of lung cancer and peripheral arterial disease. 10 Therefore, it is clear that lung cancer is closely associated with AVD. In the present study, we showed that smokers or heavy smokers with AVD were significantly associated with lung cancer. Gawenda et al. have also reported that all patients detected lung cancer before vascular surgery, were smokers. 11 Thus, it may be very important to perform a chest examination in AVD patients with smoking histories in particular.
Second, lung cancer found after AVD treatment tended to be of an advanced stage. In our series, 5 of 7 (71.4%) patients were diagnosed with stage III or IV lung cancer, and only 1 patient was able to undergo surgical resection. As a result, only 2 of 7 (28.6%) patients are alive. This may be because the time until lung cancer was detected after AVD treatment. In our series, the average time until lung cancer was detected was approximately 5 years after AVD treatment, which seemed to be too late, and routine chest follow-up examination was not performed during this period. Therefore, it may be possible to detect lung cancer earlier if the follow-up lung cancer screening is performed within 5 years after AVD treatment. Thus, we suggest that it may be necessary to routinely examine the chest of patients treated for AVD.
Third, lung cancer detected concomitantly with AVD was of an early stage, conversely. Four of 6 (66.7%) 6 In this report, 1 patient was treated simultaneously for pulmonary carcinoma and AAA and the other 13 patients underwent 2-stage treatment. Lung cancer was operated on first in 7 patients, and treatment of AAA, including aneurysmectomy or EVAR, was performed first in 6 patients. However, 1 patient underwent an urgent aneurysmectomy after chest surgery because of an AAA rupture. In the present study, all AVD concomitant with lung cancer consisted of TAA and AAA. Thus, in our institution, priority was given to 2-stage AVD treatment in all 5 cases, and there were no serious events after the postoperative course. One of the reasons for performing surgery on lung cancer prior to AVD might be the risk of disease progression in lung cancer patients in other institutions. However, we performed the lung cancer operation an average of 32 days after AVD treatment. As a result, there were no cases of disease progression between AVD and lung cancer treatments. Therefore, AVD treatment before lung cancer treatment is considered to be safe and feasible in cases in which these diseases are concomitant. In addition, EVAR has been a useful tool for aneurysm treatment. EVAR was first reported in 1986, and the 3 principal randomized trials comparing EVAR and open repair of AAA all showed a marked benefit of EVAR with respect to 30-day operative mortality. 12 Now, EVAR is widespread and has become a common treatment option. Three of 5 cases were treated by EVAR in the present study, and there were no adverse events during the postoperative course. As the use of EVAR spreads, the time interval between EVAR and surgery for lung cancer might be shortened, and the number of cases simultaneously treated for both AVD and lung cancer may increase in the future.
In conclusion, we found that both patients with a smoking history and heavy smokers were at high risk for lung cancer, and that most lung cancers detected after AVD treatment were in advanced stages and had poor prognoses. Therefore, we recommend careful and routine follow-up for screening lung cancers after AVD treatment.
